Bio-Techne price target lowered to $63 from $72 at RBC Capital

RBC Capital lowered the firm’s price target on Bio-Techne (TECH) to $63 from $72 and keeps a Sector Perform rating on the shares. The company reported a 5c beat in Q3 driven by margin outperformance, and painted a much brighter picture of the near-term outlook in LST end-markets than peers, the analyst tells investors in a research note. RBC adds however that navigating the current NIH and tariff environment will be key in de-risking FY26 numbers.